Eli Lilly History: Founding, Growth & Key Milestones

Lilly acquired Loxo Oncology in January 2019 for approximately $8 billion to acquire a precision oncology platform built around the concept of targeting specific genomic alterations in cancer regardless of tumor type. Loxo had pioneered the development of selective kinase inhibitors designed to minimize off-target effects while achieving exceptional on-target potency against genomically defined cancer populations. The acquisition was intended to accelerate Lilly's transformation into a precision medicine oncology leader at a time when the company recognized that undifferentiated cytotoxic chemotherapy partnerships were not a sustainable competitive strategy in oncology.

Lilly acquired Morphic Holding in 2024 for approximately $3.2 billion to access the company's integrin inhibitor platform, which includes MORF-057, an oral small-molecule inhibitor of alpha-4-beta-7 integrin with potential in inflammatory bowel disease including Crohn's disease and ulcerative colitis. The inflammatory bowel disease market represents a high-value segment that Lilly had not previously addressed with differentiated proprietary assets, and Morphic's oral small-molecule approach offered a potential advantage over existing large-molecule biologics like vedolizumab that require infusion or injection. The acquisition reflected Lilly's strategy of using its strong balance sheet and cash generation to acquire late-stage development assets that can be accelerated through its global clinical and commercial infrastructure.

Lilly acquired POINT Biopharma Global Inc. in late 2023 for approximately $1.4 billion to acquire the company's radioligand therapy (RLT) platform and manufacturing infrastructure. Radioligand therapies, which combine tumor-targeting molecules with radioactive isotopes to deliver targeted radiation to cancer cells, represent a rapidly advancing area of oncology following the commercial success of Novartis's Lutathera and Pluvicto. The acquisition gave Lilly access to POINT's proprietary radiopharmaceutical manufacturing facilities, a specialized industrial capability that is scarce globally, as well as a pipeline of RLT candidates in clinical development for prostate cancer and other malignancies.

Lilly acquired Prevail Therapeutics in January 2021 for approximately $1.04 billion upfront plus contingent payments to access the company's gene therapy platform targeting neurological diseases, particularly Parkinson's disease and related alpha-synucleinopathies. Prevail's lead asset, PR001, is an AAV9-based gene therapy designed to deliver a functional copy of the GBA1 gene to neurons, targeting the subset of Parkinson's disease patients with GBA1 mutations who face faster disease progression. The acquisition represented Lilly's first significant investment in the gene therapy space and reflected the company's strategy of expanding its neuroscience portfolio beyond small molecules and antibodies.

Eli Lilly and Company acquired Elizabeth Arden in 1971.